YCharOS (Antibody Characterization through Open Science)

YCharOS (Antibody Characterization through Open Science)

Alzheimer's Disease (AD)

track_changes Track Tracking Be alerted when new articles are added in this gateway (manage your tracking alerts via your account) Stop tracking this gateway
1-10 of 10 ARTICLES
https://doi.org/10.12688/f1000research.153244.3
Data Note metrics
Revised
A guide to selecting high-performing antibodies for S1PR1 (UniProt ID: P21453) for use in western blot, immunoprecipitation, and immunofluorescence
[version 3; peer review: 2 approved, 1 approved with reservations]
Peer Reviewers Melissa Pitman; Christian Tiede; Jieya Shao
  • Funders
  • Ontario Genomics
  • Mitacs
  • Genome Quebec
  • Emory-Sage-SGC TaRget Enablement to Accelerate Therapy Development for Alzheimer’s Disease
  • Genome Canada
  • National Institute on Aging
LATEST VERSION PUBLISHED 24 Jan 2025
https://doi.org/10.12688/f1000research.141800.2
Data Note metrics
Revised
Identification of high-performing antibodies for SPARC-related modular calcium-binding protein 1 (SMOC-1) for use in Western Blot and immunoprecipitation
[version 2; peer review: 2 approved]
Peer Reviewers Deborah Moshinsky; Christian Tiede
  • Funders
  • Ontario Genomics
  • Canadian Institutes of Health Research Foundation
  • Mitacs
  • Genome Quebec
  • Genome Canada
  • National Institute on Aging
LATEST VERSION PUBLISHED 05 Sep 2024
https://doi.org/10.12688/f1000research.130587.4
Data Note metrics
Revised
A guide to selecting high-performing antibodies for human Midkine for use in Western blot and immunoprecipitation
[version 4; peer review: 2 approved]
Peer Reviewers Jean-Pierre Bellier; Jens-Ulrich Rahfeld
  • Funders
  • Ontario Genomics
  • Mitacs
  • National Institutes of Aging
  • Genome Canada
LATEST VERSION PUBLISHED 01 Aug 2024
https://doi.org/10.12688/f1000research.154034.1
Data Note metrics
A guide to selecting high-performing antibodies for Synaptotagmin-1 (Uniprot ID P21579) for use in western blot, immunoprecipitation, immunofluorescence and flow cytometry
[version 1; peer review: 2 approved]
Peer Reviewers Karl D Murray; Jan Voskuil
  • Funders
  • Ontario Genomics
  • Accelerating Medicines Partnership Program for Alzheimers disease (AMD-AD)
  • Genome Quebec
  • Mitacs
  • Genome Canada
  • National Institute on Aging
PUBLISHED 19 Jul 2024
https://doi.org/10.12688/f1000research.140456.3
Data Note metrics
Revised
Identification of high-performing antibodies for tyrosine-protein kinase SYK for use in Western Blot, immunoprecipitation and immunofluorescence
[version 3; peer review: 2 approved]
Peer Reviewers Kiyonao Sada; Araujo Nelson A
  • Funders
  • Ontario Genomics
  • Canadian Institutes of Health Research Foundation
  • Genome Quebec
  • Mitacs
  • Genome Canada
  • National Institute on Aging
LATEST VERSION PUBLISHED 11 Jun 2024
https://doi.org/10.12688/f1000research.139867.2
Data Note metrics
Revised
A guide to selecting high-performing antibodies for amyloid-beta precursor protein for use in Western Blot, immunoprecipitation and immunofluorescence
[version 2; peer review: 3 approved, 1 approved with reservations]
Peer Reviewers Amal Kaddoumi; Jens-Ulrich Rahfeld; Jieya Shao; Karen Bowman
  • Funders
  • Ontario Genomics
  • Canadian Institutes of Health Research Foundation
  • Genome Quebec
  • Mitacs
  • Genome Canada
  • National Institutes of Aging
LATEST VERSION PUBLISHED 10 Apr 2024
https://doi.org/10.12688/f1000research.130991.2
Data Note metrics
Revised
A guide to selecting high-performing antibodies for Secreted frizzled-related protein 1 (sFRP-1) for use in Western Blot and immunoprecipitation
[version 2; peer review: 1 approved, 2 approved with reservations]
Peer Reviewers Viyatprajna Acharya; Oi Wah Liew; Lynne Howells
  • Funders
  • Ontario Genomics
  • Mitacs
  • National Institutes of Aging
  • Genome Canada
LATEST VERSION PUBLISHED 02 Apr 2024
https://doi.org/10.12688/f1000research.146156.1
Data Note metrics
A guide to selecting high-performing antibodies for PLC-gamma-2 for use in Western Blot, immunoprecipitation and immunofluorescence
[version 1; peer review: 2 approved]
Peer Reviewers Abhinay Ramaprasad; Deborah Moshinsky
  • Funders
  • Ontario Genomics
  • Canadian Institutes of Health Research Foundation
  • Indiana University School of Medicine Purdue University TaRget Enablement to Accelerate Therapy Development for Alzheimer’s Disease (IU-Purdue TREAT-AD)
  • Mitacs
  • Genome Québec
  • Genome Canada
  • National Institute on Aging
PUBLISHED 18 Jan 2024
https://doi.org/10.12688/f1000research.130126.3
Data Note metrics
Revised
Identification of high-performing antibodies for Moesin for use in Western Blot, immunoprecipitation, and immunofluorescence
[version 3; peer review: 1 approved, 2 approved with reservations]
Peer Reviewers Lyndsay Avery; Sungsoo Na; Emi Hibino and Yosuke Senju
  • Funders
  • Ontario Genomics
  • National Institute of Aging
  • National Institutes of Health
  • Mitacs
  • Genome Canada
LATEST VERSION PUBLISHED 01 Dec 2023
https://doi.org/10.12688/f1000research.133899.3
Data Note metrics
Revised
Identification of high-performing antibodies for Apolipoprotein E for use in Western Blot and immunoprecipitation
[version 3; peer review: 1 approved, 2 approved with reservations]
Peer Reviewers Leonard Kritharides and Maaike Kockx; Nathalie Macrez; Valerio Leoni
  • Funders
  • Bristol-Myers Squibb
  • National Institute of Aging
  • Takeda
  • Pfizer
  • Genome Quebec
  • Ontario Genomics
  • Genentech
  • Bayer AG
  • Boehringer Ingelheim
  • Merck KGaA
  • EUbOPEN
  • Mitacs
  • Ontario Genomics Institute
  • Janssen Pharmaceuticals
LATEST VERSION PUBLISHED 29 Sep 2023
1-10 of 10 ARTICLES
Gateway Areas
  • Amyotrophic Lateral Sclerosis (ALS)
    This gateway area serves as a comprehensive resource, filtering the antibody characterization articles for ALS-associated proteins nominated by the Amyotrophic Lateral Sclerosis Reproducible Antibody Platform (ALS-RAP) as well as relevant analyses and research regarding ALS and the ALS-RAP initiative.
      Read more keyboard_arrow_right
  • Alzheimer's Disease (AD)
    This gateway area functions as a complete guide to filter the antibody characterization articles for AD-associated proteins nominated by the TarGet Enablement to Accelerate Therapy Development for AD (TREAT-AD) Center or the Accelerated Medicines Partnership for AD (AMP-AD). It also provides valuable research findings pertaining to AD as well as the analysis of YCharOS’s progress in the context of the targets nominated by these two initiatives. Read more keyboard_arrow_right
  • Parkinson's disease (PD)
    This gateway area presents the antibody characterization data for protein targets nominated by the Michael J. Fox Foundation for Parkinson's Research. Read more keyboard_arrow_right
  • Rab GTPase Family
    This area serves to filter the articles providing antibody characterization data for Rab proteins, a family of over 60 small GTPases, regulating vesicle trafficking processes. Read more keyboard_arrow_right
  • NeuroDisorder Development (NDD) - Autism
    This section highlights articles featuring antibody characterization data for protein targets related to neurodevelopmental disorders (NDD) and autism. The research in this area is partially funded by the Simons Foundation Autism Research Initiative (SFARI).
      Read more keyboard_arrow_right
Our News
  • YCharOS Consensus Protocols Now Available in Nature Protocols launch

    This collaborative paper, co-authored by representatives from 11 leading antibody manufacturers and knockout cell line providers, details the YCharOS antibody characterization protocols. These protocols outline the use of knockout cell lines to evaluate antibody performance in western blotting, immunoprecipitation, and immunofluorescence. Additionally, the paper offers practical tips and best practices for antibody users.

  • YCharOS highlighted in Nature Protocols News and Views launch

    The YCharOS Consensus Protocols are further spotlighted in a Nature Protocols News and Views article by Monteiro, Voskuil, and Williams, which highlights the YCharOS platform and other complementary efforts in advancing antibody characterization.

  • YCharOS in Nature launch

    The News Feature published in Nature explores a range of initiatives aimed at tackling the antibody reliability problem. The piece spotlights YCharOS as a leading effort in this field, detailing its origins, achievements to date, and future goals.

  • Antibody Specificity: A strong case for third-party testing launch

    Article summarizing the findings from Ayoubi et al,eLife, 2023 that emphasized the extensive use of non-specific antibodies in research and presented a compelling case for third-party antibody testing.

  • Antibody characterization is critical to enhance reproducibility in biomedical research launch

    Overview of the history of the antibody characterization crisis, efforts to address the problem and actions stakeholders can take in order to increase reproducibility of research which rely on antibodies

  • YCharOS in Protocol Exchange launch

    A consensus platform for antibody characterization

  • YCharOS in eLife launch

    Scaling of an antibody validation procedure enables quantification of antibody performance in major research applications

Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.